Craft
CytoSorbents

CytoSorbents

Stock Price

$3.1

2023-02-28

Market Capitalization

$134.4 M

2023-02-28

Revenue

$43.2 M

FY, 2021

CytoSorbents Summary

Company summary

Overview
CytoSorbents Corporation is a company that provides critical care therapeutic devices that uses blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The company’s each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
Type
Public
Status
Active
Founded
2002
HQ
Princeton, NJ, US | view all locations
Website
https://cytosorbents.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Phillip P. Chan

    Phillip P. Chan, Chief Executive Officer, Director

  • Alan D. Sobel

    Alan D. Sobel, Director

    • Kathleen Bloch

      Kathleen Bloch, Chief Financial Officer

    • Vincent J. Capponi

      Vincent J. Capponi, President and Chief Operating Officer

    LocationsView all

    2 locations detected

    • Princeton, NJ HQ

      United States

      305 college road east

    • Berlin, Berlin

      Germany

      Müggelseedamm 131

    CytoSorbents Financials

    Summary financials

    Revenue (Q2, 2022)
    $8.5M
    Gross profit (Q2, 2022)
    $4.9M
    Net income (Q2, 2022)
    ($10.9M)
    Cash (Q2, 2022)
    $30.2M
    EBIT (Q2, 2022)
    ($8.4M)
    Enterprise value
    $117.7M

    Footer menu